These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 24770886)
1. Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells. Alam M; Rajabi H; Ahmad R; Jin C; Kufe D Oncotarget; 2014 May; 5(9):2622-34. PubMed ID: 24770886 [TBL] [Abstract][Full Text] [Related]
2. Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells. Raina D; Uchida Y; Kharbanda A; Rajabi H; Panchamoorthy G; Jin C; Kharbanda S; Scaltriti M; Baselga J; Kufe D Oncogene; 2014 Jun; 33(26):3422-31. PubMed ID: 23912457 [TBL] [Abstract][Full Text] [Related]
3. Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma. Jain S; Stroopinsky D; Yin L; Rosenblatt J; Alam M; Bhargava P; Clark RA; Kupper TS; Palmer K; Coll MD; Rajabi H; Pyzer A; Bar-Natan M; Luptakova K; Arnason J; Joyce R; Kufe D; Avigan D Blood; 2015 Jul; 126(3):354-62. PubMed ID: 26048911 [TBL] [Abstract][Full Text] [Related]
4. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Raina D; Kosugi M; Ahmad R; Panchamoorthy G; Rajabi H; Alam M; Shimamura T; Shapiro GI; Supko J; Kharbanda S; Kufe D Mol Cancer Ther; 2011 May; 10(5):806-16. PubMed ID: 21421804 [TBL] [Abstract][Full Text] [Related]
5. MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells. Kharbanda A; Rajabi H; Jin C; Alam M; Wong KK; Kufe D Oncotarget; 2014 Oct; 5(19):8893-905. PubMed ID: 25245423 [TBL] [Abstract][Full Text] [Related]
6. Oncogenic MUC1-C promotes tamoxifen resistance in human breast cancer. Kharbanda A; Rajabi H; Jin C; Raina D; Kufe D Mol Cancer Res; 2013 Jul; 11(7):714-23. PubMed ID: 23538857 [TBL] [Abstract][Full Text] [Related]
7. Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Raina D; Ahmad R; Joshi MD; Yin L; Wu Z; Kawano T; Vasir B; Avigan D; Kharbanda S; Kufe D Cancer Res; 2009 Jun; 69(12):5133-41. PubMed ID: 19491255 [TBL] [Abstract][Full Text] [Related]
8. Targeting MUC1-C inhibits the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer. Ahmad R; Alam M; Hasegawa M; Uchida Y; Al-Obaid O; Kharbanda S; Kufe D Mol Cancer; 2017 Feb; 16(1):33. PubMed ID: 28153010 [TBL] [Abstract][Full Text] [Related]
9. MUC1-C activates the TAK1 inflammatory pathway in colon cancer. Takahashi H; Jin C; Rajabi H; Pitroda S; Alam M; Ahmad R; Raina D; Hasegawa M; Suzuki Y; Tagde A; Bronson RT; Weichselbaum R; Kufe D Oncogene; 2015 Oct; 34(40):5187-97. PubMed ID: 25659581 [TBL] [Abstract][Full Text] [Related]
10. MUC1-C activates BMI1 in human cancer cells. Hiraki M; Maeda T; Bouillez A; Alam M; Tagde A; Hinohara K; Suzuki Y; Markert T; Miyo M; Komura K; Ahmad R; Rajabi H; Kufe D Oncogene; 2017 May; 36(20):2791-2801. PubMed ID: 27893710 [TBL] [Abstract][Full Text] [Related]
11. Dipyridamole prevents triple-negative breast-cancer progression. Spano D; Marshall JC; Marino N; De Martino D; Romano A; Scoppettuolo MN; Bello AM; Di Dato V; Navas L; De Vita G; Medaglia C; Steeg PS; Zollo M Clin Exp Metastasis; 2013 Jan; 30(1):47-68. PubMed ID: 22760522 [TBL] [Abstract][Full Text] [Related]
12. Cooperative interaction between the MUC1-C oncoprotein and the Rab31 GTPase in estrogen receptor-positive breast cancer cells. Jin C; Rajabi H; Pitroda S; Li A; Kharbanda A; Weichselbaum R; Kufe D PLoS One; 2012; 7(7):e39432. PubMed ID: 22792175 [TBL] [Abstract][Full Text] [Related]
13. MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells. Stroopinsky D; Rosenblatt J; Ito K; Mills H; Yin L; Rajabi H; Vasir B; Kufe T; Luptakova K; Arnason J; Nardella C; Levine JD; Joyce RM; Galinsky I; Reiter Y; Stone RM; Pandolfi PP; Kufe D; Avigan D Cancer Res; 2013 Sep; 73(17):5569-79. PubMed ID: 23867470 [TBL] [Abstract][Full Text] [Related]
14. miR-200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer. Tang H; Song C; Ye F; Gao G; Ou X; Zhang L; Xie X; Xie X J Cell Mol Med; 2019 Dec; 23(12):8114-8127. PubMed ID: 31599500 [TBL] [Abstract][Full Text] [Related]
15. MUC1-C oncoprotein confers androgen-independent growth of human prostate cancer cells. Rajabi H; Ahmad R; Jin C; Joshi MD; Guha M; Alam M; Kharbanda S; Kufe D Prostate; 2012 Nov; 72(15):1659-68. PubMed ID: 22473899 [TBL] [Abstract][Full Text] [Related]
16. MUC1 oncoprotein is a druggable target in human prostate cancer cells. Joshi MD; Ahmad R; Yin L; Raina D; Rajabi H; Bubley G; Kharbanda S; Kufe D Mol Cancer Ther; 2009 Nov; 8(11):3056-65. PubMed ID: 19887552 [TBL] [Abstract][Full Text] [Related]
17. Survival of human multiple myeloma cells is dependent on MUC1 C-terminal transmembrane subunit oncoprotein function. Yin L; Ahmad R; Kosugi M; Kufe T; Vasir B; Avigan D; Kharbanda S; Kufe D Mol Pharmacol; 2010 Aug; 78(2):166-74. PubMed ID: 20444960 [TBL] [Abstract][Full Text] [Related]
18. Development of the Tumor-Specific Antigen-Derived Synthetic Peptides as Potential Candidates for Targeting Breast and Other Possible Human Carcinomas. Okarvi SM; AlJammaz I Molecules; 2019 Aug; 24(17):. PubMed ID: 31470531 [TBL] [Abstract][Full Text] [Related]